GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
Top Page
GT Biopharma
(NASDAQ:GTBP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.44
▼(-39.73% Downside)
Action:Reiterated
Date:06/02/26
The score is held down primarily by weak financial performance (pre-revenue, widening losses and ongoing cash burn), partially offset by low balance-sheet leverage. Technicals show modest near-term improvement but still a longer-term downtrend, while valuation is constrained by negative earnings and no dividend support. A recent clinical-trial collaboration is a constructive catalyst but not enough to outweigh current financial risk.
Positive Factors
Clinical trial collaboration (GTB-5550)
A University of Minnesota-sponsored phase 1a/1b program materially advances GTB-5550 toward human data while shifting IND sponsorship and operational burden to an academic partner. This reduces execution risk, validates the TriKE approach if data are positive, and provides a structured, funded pathway for early clinical proof-of-concept.
Negative Factors
Pre-revenue with persistent losses
Being pre-revenue with recurring multi-year net losses limits internal funding capacity and creates dependence on external capital markets. Over the medium term this elevates dilution and execution risk, since sustained development and commercialization require substantial cash before any product revenue can offset operating losses.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical trial collaboration (GTB-5550)
A University of Minnesota-sponsored phase 1a/1b program materially advances GTB-5550 toward human data while shifting IND sponsorship and operational burden to an academic partner. This reduces execution risk, validates the TriKE approach if data are positive, and provides a structured, funded pathway for early clinical proof-of-concept.
Read all positive factors
GT Biopharma (GTBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.25M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue GrowthN/A
EPS Growth-152.00%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.46
Shares Outstanding36,062,904
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
GT Biopharma Business Overview & Revenue Model
Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology...
How the Company Makes Money
null...
GT Biopharma Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.34M | -12.42M | -13.16M | 5.98M | -20.96M | -57.48M |
| Net Income | -47.73M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
Balance Sheet | ||||||
| Total Assets | 10.00M | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Cash, Cash Equivalents and Short-Term Investments | 8.92M | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 58.00K | 174.00K | 31.00K |
| Total Liabilities | 2.42M | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Stockholders Equity | 7.58M | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
Cash Flow | ||||||
| Free Cash Flow | -13.18M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Operating Cash Flow | -13.18M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investing Cash Flow | 0.00 | 0.00 | 12.89M | -2.01M | 12.14M | -23.04M |
| Financing Cash Flow | 19.74M | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
GT Biopharma Technical Analysis
Positive
0.73
Price Trends
0.39
Positive
0.47
Negative
0.63
Negative
Market Momentum
0.02
Negative
55.18
Neutral
70.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.39, and above the 200-day MA of 0.63, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.18 is Neutral, neither overbought nor oversold. The STOCH value of 70.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GTBP.
GT Biopharma Risk Analysis
GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GT Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.02M | -0.54 | -209.36% | ― | ― | 87.76% | |
49 Neutral | $17.25M | -0.28 | -356.99% | ― | ― | -152.00% | |
45 Neutral | $5.23M | -0.73 | -203.36% | ― | ― | 93.30% | |
43 Neutral | $3.72M | -0.29 | -215.04% | ― | -100.00% | 89.96% | |
41 Neutral | $4.28M | -0.35 | -0.40% | ― | ― | 96.79% |
* Healthcare Sector Average
GTBP
GT Biopharma
0.44
-2.38
-84.33%
TOVX
Theriva Biologics
0.28
-0.19
-40.00%
REVB
Revelation Biosciences
1.09
-9.72
-89.91%
DRMA
Dermata Therapeutics
1.34
-5.70
-80.97%
CERO
CERo Therapeutics Holdings
0.01
-9.37
-99.85%
AZTR
Azitra Inc
0.22
-1.59
-87.62%
GT Biopharma Corporate Events
Business Operations and Strategy
GT Biopharma Advances GTB-5550 via University Trial Pact
Positive
Apr 7, 2026
On April 3, 2026, GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota, under which the university will sponsor an IND application and act as sponsor investigator for a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.